# Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

> **NCT00006370** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 275 (actual)

## Conditions studied

- Breast Cancer
- Lung Cancer

## Interventions

- **RADIATION:** yttrium Y 90-edotreotide

## Key facts

- **NCT ID:** NCT00006370
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006370, "Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00006370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*